Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections

Surgical Infections

Volumn 3, Issue 4, 2002, Pages 303-314

  Tellado, Jose ^a   Woods, Gail L ^b   Gesser, Richard ^b   McCarroll, Kathleen ^b   Teppler, Hedy ^b  

^a CGI Information Systems and Management Consultants Pvt Ltd   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BETA LACTAMASE INHIBITOR; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; SULTAMICILLIN; TIMENTIN;

ABDOMINAL INFECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; PELVIC INFLAMMATORY DISEASE; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; THROMBOCYTOSIS;

EID: 0036924303     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629602762539535     Document Type: Article

References (28)

1. Bartlett JG, Onderdonk AB, Louie T, et al. A review: lessons from an animal model of intra-abdominal sepsis. Arch Surg 1978;113:853-857.
2. Bennion RS, Baron EJ, Thompson JE Jr., et al. The bacteriology of gangrenous and perforated appendicitis-revisited. Ann Surg 1990;113:165-171.
3. Polk HC, Jr., Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg 1993;59:598-605.
4. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997;132:1294-1302.
5. Barie PS. Management of complicated intra-abdominal infections. J Chemother 1999;11:464-477.
6. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992;127:83-89.
7. Brook I, Frazier EH. Aerobic and anaerobic microbiology of infection after trauma. Am J Emerg Med 1998;16:585-591.
8. Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg 1990;125:1445-1451.
9. Brook I, Frazier EH. Clinical features and aerobic and anaerobic microbiologic characteristics of cellulitis. Arch Surg 1995;130:786-792.
10. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995;20(Suppl 2):S283-S288.
11. Summanen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995;20(Suppl 2):S279-S282.
12. Siami G, Christou N, Eiseman I, et al. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001;45:525-531.
13. Crombleholme WR, Ohm-Smith M, Robbie MO, et al. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol 1987;156:507-512.
14. Sweet RL, Roy S, Faro S, et al. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1994;83:280-286.
15. Roy S, Koltun W, Chatwani A, et al. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg 1998;176(Suppl 6A):67S-73S.
16. Gall S. Therapeutic dilemmas in the treatment of pelvic infections. J Reprod Med 1990;35(Suppl):1091-1094.
17. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-1867.
18. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1915-1918.
19. Beam TR, Jr, Gilbert DN, Kunin DM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992;15(Suppl 1):S5-S32.
20. Graham D, Lucasti C, Malafaia O, et al. Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002;34:1460-1468.
21. Solomkin JS, Yellin AE, Rotstein OD, et al. Results of a double-blind, randomized, comparative trial of ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg (in press).
22. Roy S, Higareda I, Angel-Muller E, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infect Dis Obstet Gynecol (in press).
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. NCCLS document M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
24. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved Standard, M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
25. Finegold SM, Baron EJ, Wexler HM. A clinical guide to anaerobic infections. STAR Publishing Company, Belmont, CA, 1992.
26. Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP Ann Pharmacother 1991;25:546-552.
27. Nettleman MD, Bock MJ. The epidemiology of missed medication doses in hospitalized patients. Clin Perform Qual Health Care 1996;4:148-153.
28. Physicians' Desk Reference®. 56th ed. Montvale, NJ. Medical Economics, 2002.